Metabolic profile and adipokines in cardio-reno metabolic syndrome stages 1 and 2 in young people

Objective: to compare metabolic parameters and adipokine levels in cardiorenal metabolic syndrome (CRMS) stages 1 and 2 in young individuals aged 25–44 years.

Materials and methods: a cross-sectional study based on a prospective cohort study included 120 people aged 25–44 years: group 1 (controls) — young individuals without cardiometabolic risk factors, stage 0 (n=40), group 2 — young individuals with CMS stage 1 (n=40), group 3 — young individuals with CMS stage 2 (n=40).

Results: the most significant differences in the groups with stage 1 and 2 CRMS were observed for HOMA-IR index, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and uric acid in comparison with the control group. The most common cardiometabolic risk factors in the group with stage 2 CRMS were overweight/obesity, hyperlipidemia, hyperglycemia, arterial hypertension, hyperuricemia, and a burdened heredity for cardiovascular diseases. The serum concentration of leptin was highest in women with stage 1 and 2 CRMS, whereas the serum concentration of adiponectin was lower in all individuals with stage 1 and 2 CRMS than in the control group, with no gender differences.

Conclusion: modern approaches to the stages of CRMS contribute to the integration of cardiovascular diseases and metabolic disorders as components of a single pathophysiological process. They also allow a comprehensive and quantitative assessment of the likelihood of cardiovascular disease and type 2 diabetes mellitus. Measuring serum cytokine levels can serve as an effective tool for assessing overall cardiometabolic risk and predicting the development of cardiovascular diseases and type 2 diabetes mellitus.

1. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. Erratum in: Circulation. 2024;149(13):e1023. DOI: 10.1161/CIR.0000000000001184

2. DOI: 10.33978/2307–3586–2023–19–52–14–28

3. Larqué E, Labayen I, Flodmark CE, Lissau I, Czernin S, Moreno LA, et al. From conception to infancy - early risk factors for childhood obesity. Nat Rev Endocrinol. 2019;15(8):456-478. DOI: 10.1038/s41574-019-0219-1

4. Chulkov V.S., Lenets E.A., Chulkov V.S., Gavrilova E.S., Minina E.E., Zhdanova O.V. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. Arterial Hypertension. 2020;26(4):371–382. (In Russ.) DOI: 10.18705/1607–419X–2020–26–4–371–382

5. Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019;20(9):2358. DOI: 10.3390/ijms20092358

6. Arabidze G.G., Mamedov M.N. Cardiovascular-kidney-metabolic syndrome – a new concept of the association of risk factors and metabolic disorders within the cardiovascular and renal continuum. View on the issue. Russian Journal of Cardiology. 2024;29(5):5772. (In Russ.) DOI: 10.15829/1560–4071–2024–5772

7. Sorimachi H, Obokata M, Omote K, Reddy YNV, Takahashi N, Koepp KE, et al. Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery. J Am Coll Cardiol. 2022;80(16):1501-1512. DOI: 10.1016/j.jacc.2022.08.738

8. Izmaylova M.Y., Demidova T.Yu., Valentovich V.V. Cardio-reno-Metabolic health: discussing the recommendations of the American Heart Association. FOCUS Endocrinology. 2024;2(5):35–45. (In Russ.) DOI: 10.62751/2713–0177–2024–5–2–16

9. Drapkina O.M., Kim O.T. Sex and gender differences in health and disease. Part II. Clinical and medical-social. Cardiovascular Therapy and Prevention. 2023;22(12):3831. (In Russ.) DOI: 10.15829/10.15829/1728–8800–2023–3831

10. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) DOI: 10.15829/1560–4071–2020–3–3786

11. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020;17(1):7–45. (In Russ.) DOI: 10.26442/2075082X.2020.1.200051

12. Khan AR, Salama AH, Aleem Z, Alfakeer H, Alnemr L, Shareef AMM. The Promising Frontier of Cardiometabolic Syndrome: A New Paradigm in Cardiology. Cureus. 2023;15(9):e45542. DOI: 10.7759/cureus.45542

13. Howell CR, Zhang L, Mehta T, Wilkinson L, Carson AP, Levitan EB, et al. Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts. JACC Adv. 2024;3(4):100868. DOI: 10.1016/j.jacadv.2024.100868

14. Tarasova O.A., Chulkov V.S., Sinitsin S.P., Vereina N.K., Chulkov V.S. Risk factors for cardiovascular complications in women with hypertensive disorders during pregnancy. Arterial Hypertension. 2019;25(1):97–104. (In Russ.) DOI: 10.18705/1607–419X–2019–25–1–97–104

15. Tarasova O.А., Chulkov V.S., Chulkov V.S., Ektova N.A. Cardiometabolic profile in women after pregnancy hypertension: propency score matching. South Russian Journal of Therapeutic Practice. 2023;4(1):75–81. (In Russ.) DOI: 10.21886/2712–8156–2023–4–1–75–81

16. Deemer S., Garvey W.T. CMDS is a practical clinical estimate of insulin resistance in adults with overweight/obesity. Obesity. 2020;28(S2):68.

17. Li G, Xu L, Zhao Y, Li L, Fu J, Zhang Q, et al. Leptin-adiponectin imbalance as a marker of metabolic syndrome among Chinese children and adolescents: The BCAMS study. PLoS One. 2017;12(10):e0186222. DOI: 10.1371/journal.pone.0186222

18. Chulkov V.S., Lenets E.A., Gavrilova E.S., Minina E.E., Pozdeeva V.A., Ukolov N.D. Gender differences in cardiometabolic risks among young adults. Complex Issues of Cardiovascular Diseases. 2021;10(2):94–98. (In Russ.) DOI: 10.17802/2306–1278–2021–10–2S–94–98

19. Vilariño-García T, Polonio-González ML, Pérez-Pérez A, Ribalta J, Arrieta F, Aguilar M, et al. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. Int J Mol Sci. 2024;25(4):2338. DOI: 10.3390/ijms25042338